US Drug Recall Register

FDA Drug Recalls

1,709 recalls · Class III, newest first

Class III · Low risk Terminated

Levetiracetam Injection

Reason Labeling: Incorrect or Missing Package Insert - the incorrect package insert version was attached.

X-Gen Pharmaceuticals Inc. NDC 39822-4000-1 D-0519-2020
Class III · Low risk Terminated

Motion Sickness Strips

Reason Subpotent Drug

Sato Pharmaceutical Inc. NDC 69842-288-01 D-0325-2020
Class III · Low risk Terminated

Wal-Dram 2

Reason Subpotent Drug

Sato Pharmaceutical Inc. NDC 0363-1407-01 D-0324-2020
Class III · Low risk Terminated

Motion Sickness

Reason Subpotent Drug

Sato Pharmaceutical Inc. NDC 59779-534-01 D-0323-2020
Class III · Low risk Terminated

Zentrip

Reason Subpotent Drug

Sato Pharmaceutical Inc. NDC 49873-803-01 D-0322-2020
Class III · Low risk Terminated

Sankaijo BOTANICAL LAXATIVE

Reason Subpotent Drug: Formulated amount of sennosides component is less than labelled claim.

Sato Pharmaceutical Inc. NDC 49873-404-01 D-0303-2020
Class III · Low risk Terminated

Testosterone Cypionate Injection

Reason Labeling:Label Mix-up: Shipper Carton labelled Testosterone Cypionate Injection, USP, 200mg/mL, 1 ml single-dose vials, found to contain shelf cartons labelled as Testosterone Cypionate Injection USP, 200mg/mL, 10 ml multi-dose vials which contain Testosterone Cypionate Injection USP, 200mg/mL,1mL single-does vials

Arbor Pharmaceuticals Inc. NDC 52536-625-01 D-0167-2020
Class III · Low risk Terminated

Benazepril HCl Tablets

Reason Presence of Foreign Tablet/Capsule; Promethazine HCl tablet found in the Benazepril HCl bottle

Amneal Pharmaceuticals, Inc. NDC 65162-754-10 D-0134-2020
Class III · Low risk Ongoing

Ranitidine Tablets USP

Reason CGMP DEVIATIONS: One lot of Ranitidine Tablets USP, 150 mg is being recalled because some bottles were empty.

AuroMedics Pharma LLC NDC 55910-092-79 D-0166-2020
Class III · Low risk Terminated

Sodium Chloride Injection USP 0.9%

Reason Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.

Guerbet LLC NDC 0019-1188-27 D-0138-2020
Class III · Low risk Terminated

Zarontin

Reason Labeling: Incorrect or Missing Lot and/or Exp Date. The expiry date on the product label is incorrect. The label states an expiry date of 09/2021 when it should be 09/2020.

Pfizer Inc. NDC 0071-0237-24 D-0002-2020
Class III · Low risk Terminated

ethosuximide capsules

Reason Labeling: Incorrect or Missing Lot and/or Exp Date. The expiry date on the product label is incorrect. The label states an expiry date of 09/2021 when it should be 09/2020.

Pfizer Inc. NDC 59762-2250-2 D-0001-2020
Class III · Low risk Terminated

Gatifloxacin Ophthalmic Solution 0.5%

Reason Failed Impurities/Degradation Specifications:OOS for unknown impurity.

Mylan Pharmaceuticals Inc. D-1848-2019
Class III · Low risk Terminated

Matzim LA

Reason GMP Deviation: lot not intended for commercial distribution.

Teva Pharmaceuticals USA NDC 52544-692-30 D-0131-2020
Class III · Low risk Terminated

Lamivudine Tablets

Reason Labeling: Incorrect or Missing Package Insert; an error in the Dosage Forms and Strengths section of the insert that incorrectly lists the tablet description coding for the tablets.

American Health Packaging NDC 60687-362-21 D-1847-2019
Class III · Low risk Terminated

minolira

Reason Failed Dissolution Specifications:

EPI Health, LLC NDC 71403-102-05 D-0120-2020
Class III · Low risk Terminated

Pramipexole Dihydrochloride Tablets 0.125 mg

Reason Subpotent Drug: Out of specification result during stability study in Pramipexole Dihydrochloride Tablets 0.125 mg

Macleods Pharma Usa Inc NDC 33342-031-10 D-1851-2019
Class III · Low risk Terminated

Eptifibatide Injection

Reason Failed Impurities/Degradation Specifications: Out of Specification (OOS) for known impurity, D-aspartic acid.

Akorn, Inc. NDC 17478-902-10 D-1841-2019
Class III · Low risk Terminated

Eptifibatide Injection

Reason Short Fill: fill volume was out of specification at 94 mL (specification: no less than 100 mL) and Failed Impurities/Degradation Specifications: Out of Specification (OOS) for known impurity, D-aspartic acid.

Akorn, Inc. NDC 17478-903-90 D-1840-2019
Class III · Low risk Terminated

Eptifibatide Injection

Reason Failed Impurities/Degradation Specifications: Out of Specification (OOS) for known impurity, D-aspartic acid.

Akorn, Inc. NDC 17478-903-90 D-1839-2019
Class III · Low risk Terminated

Simvastatin Tablets

Reason Labeling; Incorrect or Missing Lot and/or Exp Date; some bottles labeled with lot number 05318054B instead of 05318034B

Aurobindo Pharma USA Inc. NDC 65862-053-99 D-1842-2019
Class III · Low risk Terminated

Methylergonovine Maleate USP 0.2 mg Tablets a) 12 count

Reason Presence of Foreign Tablet/Capsule; one Promethazine tablet was found in a bottle of Methylergonovine Maleate tablets

Amneal Pharmaceuticals, Inc. NDC 69238-1605-02 D-1516-2019
Class III · Low risk Terminated

Nystatin and Triamcinolone Acetonide Cream USP100

Reason Failed Content Uniformity Specifications: Out-of-specification result observed in uniformity of containers test at 9 month long term stability condition for upright orientation.

Lupin Pharmaceuticals Inc. NDC 68180-545-01 D-1518-2019